Answers are grounded in this paper and cite their sources.
Obesity-driven insulin resistance and chronic inflammation present pressing therapeutic challenges, necessitating innovative strategies that target underlying metabolic dysregulation. Here, we report the development of stearic acid-modified hexavanadate (SA-V6) vesicles, a self-assembling nanoplatform engineered for efficient loading and delivery of Palmitic acid hydroxystearic acids (PAHSAs). In a high-fat diet (HFD)-induced murine obesity model, SA-V6/HFAE vesicles exhibited enhanced intestinal absorption, synergistically alleviating glucose-lipid metabolic disturbances via augmented insulin and glucagon-like peptide (GLP-1) secretion, as evidenced by improved glycemic control and normalized serum lipid profiles. Furthermore, the hybrid vesicles suppressed proinflammatory cytokine secretion in adipose tissue while activating the GPR120 and insulin signaling axis, a dual mechanism critical to restoring metabolic homeostasis. By integrating nanomaterial design with multifunctional bioactive cargo, this work establishes a promising therapeutic approach to address obesity-associated metabolic dysfunction and inflammation. The dual action of SA-V6/HFAE vesicles in enhancing insulin and GLP-1 secretion, alongside GPR120 pathway activation, highlights their potential as a translatable platform for precision management of complex metabolic disorders.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: